The difference between lupus nephritis class IV-G and IV-S in Koreans: Focus on the response to cyclophosphamide induction treatment

Rheumatology

Volumn 47, Issue 3, 2008, Pages 311-314

  Kim, Y G ^a   Kim, H W ^a   Cho, Y M ^a   Oh, J S ^a   Nah, S S ^a   Lee, C K ^a   Yoo, B ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Cyclophosphamide; Lupus nephritis; Remission induction

Indexed keywords

CYCLOPHOSPHAMIDE; DOUBLE STRANDED DNA ANTIBODY; METHYLPREDNISOLONE; PROTEIN;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; DISEASE CLASSIFICATION; DRUG DOSE REDUCTION; DRUG RESPONSE; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; KIDNEY BIOPSY; KOREA; LOW DRUG DOSE; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEIN URINE LEVEL; REMISSION; RETROSPECTIVE STUDY;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HUMANS; IMMUNOHISTOCHEMISTRY; INFUSIONS, INTRAVENOUS; KOREA; LUPUS NEPHRITIS; MALE; PROBABILITY; REMISSION INDUCTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 39449111880     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kem365     Document Type: Article

References (18)

1. Mok CC, Ho CT, Siu YP et al. Treatment of diffuse proliferative lupus glomerulonephritis: A comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis 2001;38:256-64.
2. Boumpas DT, Austin HA, III, Vaughn EM et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5.
3. Boumpas DT, Fessler BJ, Austin HA, III, Below JE, Klippel JH, Lockshin MD. Systemic lupus erythematosus: Emerging concepts. Part 2: dermatologic and joint disease, the antiphospholipid antibody syndrome, pregnancy and hormonal therapy, morbidity and mortality, and pathogenesis. Ann Intern Med 1995;123:42-53.
4. Dooley MA, Falk RJ. Human clinical trials in lupus nephritis. Semin Nephrol 2007;27:115-27.
5. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory Systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006;54:2970-82.
6. Weaning JJ, D'Agati VD, Schwartz MM et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004;65:521-30.
7. Mittal B, Hurwitz S, Rennke H, Singh AK. New subcategories of class IV lupus nephritis: Are there clinical, histologic, and outcome differences? Am J Kidney Dis 2004;44:1050-9.
8. Yokoyama. H, Wada T, Here A et al. The outcome and a new ISN/RPS 2003 classification of lupus nephritis in Japanese. Kidney Int 2004;66:2382-8.
9. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
10. McCluskey RT. Lupus nephritis. In: Somers SC, ed. Kidney pathology decennial, 1966-1975. New York: Appleton-Century-Crofts, 1975;435-50.
11. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. A disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum 1992;35:630-40.
12. Austin HA III, Muenz LR, Joyce KM et al. Prognostic factors in lupus; naphritis. Contribution of renal histologic data. Am J Med 1983;75:302-91.
13. Najafi CC, Korbet SM, Lewis EJ, Schwartz MM, Reichlin M, Evans J. Significance of histologic patterns of glomerular injury upon long-term prognosis in some lupus glomerulonephritis. Kidney Int 2001;59:2156-63.
14. Housslau FA, Vasconcelos C, D'Cruz D et al. Immunosuppressive therapy in lupus nephritis: The Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-31.
15. Mok CC, Ying KY, Ng WL et al. Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 2006;119:355 e25-33.
16. Ginzler EM, Dooley MA, Aranow C et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus naphritis. N Engl J Med 2005;353:2219-28.
17. Hill GS, Delahousse M, Nochy D, Bariety J. Class IV-S versus class IV-G lupus nephritis: Clinical and morphologic differences suggesting different pathogenesis. Kidney Int 2005;68:2288-97.
18. Mok CC, Ying KY, Tang S et al. Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 2004;50:2559-68.